CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 4.6: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.39BCNY505.84M · vs all stocks (USD)
Revenue (TTM)
310.89MCNY46.41M · vs all stocks (USD)
Profit Margin
-8.20%vs Biotechnology peers
Beta
0.7580xvs all stocks
52-Week Change
-38.41%vs all stocks
Market Capitalization
3.39BCNY505.84M · vs all stocks (USD)
Enterprise Value
1.97BCNY294.24M · vs all stocks (USD)
Price to Sales (TTM)
10.62xvs Biotechnology peers
Price to Book (MRQ)
1.12xvs Biotechnology peers
Enterprise to Revenue
6.34xvs Biotechnology peers
Enterprise to EBITDA
-177.21xvs Biotechnology peers
Gross Margin
68.86%vs Biotechnology peers
Profit Margin
-8.20%vs Biotechnology peers
Operating Margin
-19.58%vs Biotechnology peers
Return on Assets (TTM)
-0.97%vs Biotechnology peers
Return on Equity (TTM)
-0.82%vs Biotechnology peers
Revenue (TTM)
310.89MCNY46.41M · vs all stocks (USD)
Revenue per Share (TTM)
2.62CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-18.00%vs Biotechnology peers
Gross Profit (TTM)
178.68MCNY26.67M · vs all stocks (USD)
EBITDA (TTM)
8.58MCNY1.28M · vs all stocks (USD)
Net Income (TTM)
-25.51MCNY-3.81M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-24.85%vs Biotechnology peers
Operating Cash Flow (TTM)
26.10MCNY3.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
13.56MCNY2.02M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
339.05MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
124.92MCNYFY2025 · Dec 31, 2025Gross Profit
214.13MCNYFY2025 · Dec 31, 2025Operating Income
-58.97MCNY-8.80M · vs all stocks (USD)
Pre-tax Income
-32.06MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.02MCNYFY2025 · Dec 31, 2025Net Income
-41.08MCNYFY2025 · Dec 31, 2025EBIT
-23.53MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
8.58MCNYFY2025 · Dec 31, 2025Research & Development
78.72MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
67.53MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.19MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.53MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4900CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
83.83MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
83.83MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.08MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-47.17MCNYFY2025 · Dec 31, 2025Free Cash Flow
-110.37MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
483.51MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.08MCNYFY2025 · Dec 31, 2025Other Non-cash Items
37.61MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-44.46MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
763.74KCNYFY2025 · Dec 31, 2025Capital Expenditures
-63.20MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.53BCNYFY2025 · Dec 31, 2025Sale of Investments
4.40BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-193.29MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
648.04MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-510.40MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-293.07MCNYFY2025 · Dec 31, 2025Other Financing Charges
-6.68MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-162.11MCNYFY2025 · Dec 31, 2025Shares Outstanding
124.13MSharesUpdated Sep 22, 2026Float Shares
63.12MSharesUpdated Sep 22, 2026% Held by Insiders
46.42%vs all stocks
% Held by Institutions
0.92%vs all stocks
Total Cash (MRQ)
1.71BCNY255.73M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.80CNYUpdated Sep 22, 2026Total Debt (MRQ)
553.83MCNY82.67M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1881xvs Biotechnology peers
Current Ratio (MRQ)
3.08xvs Biotechnology peers
Book Value per Share (MRQ)
23.71CNYUpdated Sep 22, 2026Total Assets
3.55BCNY530.56M · vs all stocks (USD)
Total Current Assets
1.69BCNYFY2025 · Dec 31, 2025Total Liabilities
625.71MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.86BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
158.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
467.58MCNYFY2025 · Dec 31, 2025Cash
450.80MCNYFY2025 · Dec 31, 2025Cash Equivalents
32.97MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
483.77MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.10BCNYFY2025 · Dec 31, 2025Accounts Receivable
39.41MCNYFY2025 · Dec 31, 2025Inventory
51.50MCNYFY2025 · Dec 31, 2025Accounts Payable
60.50MCNYFY2025 · Dec 31, 2025Short-term Debt
321.47MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.92MCNYFY2025 · Dec 31, 2025Long-term Debt
55.62MCNYFY2025 · Dec 31, 2025Common Stock (Book)
83.87MCNYFY2025 · Dec 31, 2025Retained Earnings
2.18BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.93BCNY437.16M · vs all stocks (USD)
52-Week Low
23.24CNYUpdated Sep 22, 202652-Week High
63.51CNYUpdated Sep 22, 202652-Week Change
-38.41%vs all stocks
Beta
0.7580xvs all stocks
50-Day MA
28.06CNYUpdated Sep 22, 2026200-Day MA
37.94CNYUpdated Sep 22, 2026Avg 10-Day Volume
1.30MSharesUpdated Sep 22, 2026Avg 30-Day Volume
1.55MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.2000CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.69Profit Margin: -0.08
Financial Health
Altman Z-Score 4.6: safe zoneNotable
Altman Z-Score: 4.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Puma Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Boryung Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacific Biosciences of California, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bright Minds Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Succeeder Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Hanbon Science & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qingdao Vland Biotech Inc.
Tier 1ProductionApproval-Gated PipelineFlow
Ningbo David Medical Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule